DE60237671D1 - Implantierbare vorrichtung enthaltend resorbierbares matrixmaterial und antiproliferative wirkstoffe zur vorbeugung oder behandlung von versagen vaskulärer hämodialysezugänge und anderer vaskulärer transplantate - Google Patents

Implantierbare vorrichtung enthaltend resorbierbares matrixmaterial und antiproliferative wirkstoffe zur vorbeugung oder behandlung von versagen vaskulärer hämodialysezugänge und anderer vaskulärer transplantate

Info

Publication number
DE60237671D1
DE60237671D1 DE60237671T DE60237671T DE60237671D1 DE 60237671 D1 DE60237671 D1 DE 60237671D1 DE 60237671 T DE60237671 T DE 60237671T DE 60237671 T DE60237671 T DE 60237671T DE 60237671 D1 DE60237671 D1 DE 60237671D1
Authority
DE
Germany
Prior art keywords
vascular
hemodialysis
accumulations
preventing
active substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60237671T
Other languages
English (en)
Inventor
Sriram S Iyer
Nicholas N Kipshidze
Victor V Nikolaychik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vascular Therapies Inc
Original Assignee
Vascular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Therapies Inc filed Critical Vascular Therapies Inc
Application granted granted Critical
Publication of DE60237671D1 publication Critical patent/DE60237671D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/225—Fibrin; Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A61M1/3653—Interfaces between patient blood circulation and extra-corporal blood circuit
    • A61M1/3655—Arterio-venous shunts or fistulae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/02—Access sites
    • A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/02—Access sites
    • A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
    • A61M2039/0258—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body for vascular access, e.g. blood stream access
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/02—Access sites
    • A61M39/0247—Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
    • A61M2039/0261—Means for anchoring port to the body, or ports having a special shape or being made of a specific material to allow easy implantation/integration in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A61M2202/0478—Heparin
DE60237671T 2001-01-16 2002-01-16 Implantierbare vorrichtung enthaltend resorbierbares matrixmaterial und antiproliferative wirkstoffe zur vorbeugung oder behandlung von versagen vaskulärer hämodialysezugänge und anderer vaskulärer transplantate Expired - Lifetime DE60237671D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26213201P 2001-01-16 2001-01-16
PCT/US2002/001375 WO2002062335A2 (en) 2001-01-16 2002-01-16 Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts

Publications (1)

Publication Number Publication Date
DE60237671D1 true DE60237671D1 (de) 2010-10-28

Family

ID=22996277

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60237671T Expired - Lifetime DE60237671D1 (de) 2001-01-16 2002-01-16 Implantierbare vorrichtung enthaltend resorbierbares matrixmaterial und antiproliferative wirkstoffe zur vorbeugung oder behandlung von versagen vaskulärer hämodialysezugänge und anderer vaskulärer transplantate

Country Status (18)

Country Link
US (5) US6726923B2 (de)
EP (2) EP1351681B1 (de)
JP (2) JP4584537B2 (de)
CN (1) CN1492759A (de)
AP (1) AP2003002828A0 (de)
AT (1) ATE481097T1 (de)
AU (1) AU2002249958B2 (de)
BR (1) BR0206464A (de)
CA (1) CA2434972C (de)
CY (1) CY1119109T1 (de)
DE (1) DE60237671D1 (de)
DK (1) DK2314293T3 (de)
ES (1) ES2621652T3 (de)
MX (1) MXPA03006315A (de)
NZ (1) NZ527046A (de)
PT (1) PT2314293T (de)
RU (1) RU2345719C2 (de)
WO (1) WO2002062335A2 (de)

Families Citing this family (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697108B2 (en) * 1994-05-13 2014-04-15 Kensey Nash Corporation Method for making a porous polymeric material
US8795242B2 (en) * 1994-05-13 2014-08-05 Kensey Nash Corporation Resorbable polymeric device for localized drug delivery
US7963997B2 (en) * 2002-07-19 2011-06-21 Kensey Nash Corporation Device for regeneration of articular cartilage and other tissue
AU737078C (en) * 1996-05-24 2002-05-02 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways
US7959664B2 (en) * 1996-12-26 2011-06-14 Medinol, Ltd. Flat process of drug coating for stents
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US7399480B2 (en) * 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US8057816B2 (en) * 1997-09-26 2011-11-15 Abbott Laboratories Compositions and methods of administering paclitaxel with other drugs using medical devices
US8257726B2 (en) * 1997-09-26 2012-09-04 Abbott Laboratories Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
US20020099438A1 (en) 1998-04-15 2002-07-25 Furst Joseph G. Irradiated stent coating
US20030040790A1 (en) * 1998-04-15 2003-02-27 Furst Joseph G. Stent coating
US7967855B2 (en) * 1998-07-27 2011-06-28 Icon Interventional Systems, Inc. Coated medical device
US8070796B2 (en) 1998-07-27 2011-12-06 Icon Interventional Systems, Inc. Thrombosis inhibiting graft
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
DE60124285T3 (de) † 2000-09-29 2011-03-17 Cordis Corp., Miami Lakes Beschichtete medizinische geräte
US20050084514A1 (en) * 2000-11-06 2005-04-21 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
US20040241211A9 (en) * 2000-11-06 2004-12-02 Fischell Robert E. Devices and methods for reducing scar tissue formation
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US6808518B2 (en) 2001-09-28 2004-10-26 Ethicon, Inc. Methods and devices for treating diseased blood vessels
US8740973B2 (en) * 2001-10-26 2014-06-03 Icon Medical Corp. Polymer biodegradable medical device
US20030163144A1 (en) * 2002-02-28 2003-08-28 Weadock Kevin S. Sponge for creating an anastomosis between vessels
JP4265888B2 (ja) * 2002-06-12 2009-05-20 株式会社リコー 画像形成装置
US7361368B2 (en) * 2002-06-28 2008-04-22 Advanced Cardiovascular Systems, Inc. Device and method for combining a treatment agent and a gel
EP1539032A2 (de) * 2002-07-02 2005-06-15 Polycord, Inc. Polymerisierte und modifizierte rapamycine und ihre verwendung bei der beschichtung medizinischer prothesen
AU2003248847A1 (en) * 2002-07-09 2004-01-23 Eva Corporation Delivery apparatus for use during a surgical procedure and method of using the same
US8016881B2 (en) * 2002-07-31 2011-09-13 Icon Interventional Systems, Inc. Sutures and surgical staples for anastamoses, wound closures, and surgical closures
US20050163821A1 (en) * 2002-08-02 2005-07-28 Hsing-Wen Sung Drug-eluting Biodegradable Stent and Delivery Means
US7438925B2 (en) 2002-08-26 2008-10-21 Biovention Holdings Ltd. Drug eluting coatings for medical implants
WO2004022124A1 (en) * 2002-09-06 2004-03-18 Abbott Laboratories Medical device having hydration inhibitor
DK1539157T3 (da) 2002-09-18 2013-10-07 Univ Pennsylvania Fremgangsmåde til hæmning af choroidal neovaskularisering
JP2006515186A (ja) * 2002-09-26 2006-05-25 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 血管周囲ラップ
AU2002953440A0 (en) * 2002-12-19 2003-01-09 Unisearch Limited A method of treating a stiffened vessel
MXPA05009553A (es) * 2003-03-10 2006-03-17 Broin And Associates Inc Metodo para producir etanol utilizando almidon como materia prima.
US20050233030A1 (en) * 2004-03-10 2005-10-20 Broin And Associates, Inc. Methods and systems for producing ethanol using raw starch and fractionation
EP1460088A1 (de) 2003-03-21 2004-09-22 Biotest AG Humanisierter Antikörper gegen CD4 mit immunsuppressiven Merkmalen
US8383158B2 (en) * 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US8821473B2 (en) 2003-04-15 2014-09-02 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
ES2452731T3 (es) * 2003-06-19 2014-04-02 Vascular Therapies, Llc Dispositivo de cierre vascular
CA2536042A1 (en) * 2003-11-10 2005-06-02 Angiotech International Ag Medical implants and anti-scarring agents
US7553326B2 (en) 2003-11-24 2009-06-30 Sweet Richard M Method and apparatus for preventing dialysis graft intimal hyperplasia
US7211108B2 (en) * 2004-01-23 2007-05-01 Icon Medical Corp. Vascular grafts with amphiphilic block copolymer coatings
US20050239181A1 (en) * 2004-03-10 2005-10-27 Broin And Associates, Inc. Continuous process for producing ethanol using raw starch
US20070027523A1 (en) * 2004-03-19 2007-02-01 Toner John L Method of treating vascular disease at a bifurcated vessel using coated balloon
EP2301619B1 (de) * 2004-03-19 2017-05-10 Abbott Laboratories Abgabe mehrerer Arzneimittel aus einem Ballon und Prothese
US20100030183A1 (en) * 2004-03-19 2010-02-04 Toner John L Method of treating vascular disease at a bifurcated vessel using a coated balloon
US8431145B2 (en) 2004-03-19 2013-04-30 Abbott Laboratories Multiple drug delivery from a balloon and a prosthesis
US8000784B2 (en) * 2004-04-19 2011-08-16 The Invention Science Fund I, Llc Lumen-traveling device
KR100596218B1 (ko) * 2004-06-10 2006-07-03 (주)액세스 플러스 약물이 표면처리된 혈액투석환자의 동정맥 연결용 튜브
US20060009839A1 (en) * 2004-07-12 2006-01-12 Scimed Life Systems, Inc. Composite vascular graft including bioactive agent coating and biodegradable sheath
WO2006017275A1 (en) 2004-07-13 2006-02-16 The University Of Tennessee Research Foundation Adhesive composition for carrying therapeutic agents as delivery vehicle on coatings applied to vascular grafts
US11207457B2 (en) 2004-08-27 2021-12-28 Edwards Lifesciences Corporation Device and method for establishing an artificial arterio-venous fistula
CA2577108A1 (en) 2004-08-31 2006-03-09 C.R. Bard, Inc. Self-sealing ptfe graft with kink resistance
US20060106406A1 (en) * 2004-09-27 2006-05-18 Judah Weinberger Methods and devices for extravascular intervention
US20060069426A1 (en) * 2004-09-27 2006-03-30 Weinberger Judah Z Methods and devices for extravascular intervention
US20060135970A1 (en) 2004-11-15 2006-06-22 Laurent Schaller Catheter-based tissue remodeling devices and methods
US7993738B2 (en) * 2004-11-30 2011-08-09 The Regents Of The University Of Michigan Modified porous materials and method of forming the same
WO2006062909A2 (en) * 2004-12-08 2006-06-15 Pervasis Therapeutics, Inc. Methods and compositions for enhancing vascular access
EP1824526B1 (de) * 2004-12-08 2009-12-02 Pervasis Therapeutics, Inc. Materialien und verfahren zur minimal invasiven abgabe einer zellhaltigen fliessfähigen zusammensetzung
BRPI0607606B1 (pt) 2005-02-09 2021-06-22 Santen Pharmaceutical, Co., Ltd. Formulação líquida
US9107899B2 (en) 2005-03-03 2015-08-18 Icon Medical Corporation Metal alloys for medical devices
WO2006110197A2 (en) * 2005-03-03 2006-10-19 Icon Medical Corp. Polymer biodegradable medical device
US20060264914A1 (en) * 2005-03-03 2006-11-23 Icon Medical Corp. Metal alloys for medical devices
US7540995B2 (en) 2005-03-03 2009-06-02 Icon Medical Corp. Process for forming an improved metal alloy stent
US20060201601A1 (en) * 2005-03-03 2006-09-14 Icon Interventional Systems, Inc. Flexible markers
US8323333B2 (en) * 2005-03-03 2012-12-04 Icon Medical Corp. Fragile structure protective coating
EP1858440B1 (de) * 2005-03-03 2024-04-24 MiRus LLC Verbesserte metalllegierungen für ein medizinprodukt
EP1877004A4 (de) * 2005-03-23 2012-01-25 Abbott Lab Zusammensetzungen und verfahren zur verabreichung von rapamycin-analoga mit medizinprodukten für langzeitwirkung
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US8828433B2 (en) * 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
CA2605080A1 (en) 2005-04-21 2006-11-02 Massachusetts Institute Of Technology Materials and methods for altering an immune response to exogenous and endogenous immunogens, including syngeneic and non-syngeneic cells, tissues or organs
US8333777B2 (en) 2005-04-22 2012-12-18 Benvenue Medical, Inc. Catheter-based tissue remodeling devices and methods
US20070037267A1 (en) * 2005-05-02 2007-02-15 Broin And Associates, Inc. Methods and systems for producing ethanol using raw starch and fractionation
US8002738B2 (en) * 2005-05-17 2011-08-23 Boston Scientific Scimed, Inc. Self-adhering lesion formation apparatus and methods
EP1887968A4 (de) * 2005-06-08 2013-01-23 Bard Inc C R Transplantate und stents mit anorganischem biokompatiblem calciumsalz
WO2007001472A2 (en) 2005-06-17 2007-01-04 C. R. Bard, Inc. Vascular graft with kink resistance after clamping
SG161258A1 (en) 2005-06-21 2010-05-27 Pervasis Therapeutics Inc Methods and compositions for enhancing vascular access
JP5118042B2 (ja) * 2005-09-06 2013-01-16 シー・アール・バード・インコーポレーテッド 薬物結晶を含有する移植用インプラント
US7219021B2 (en) * 2005-09-13 2007-05-15 Honeywell International Inc. Multiple wireless sensors for dialysis application
US7919289B2 (en) 2005-10-10 2011-04-05 Poet Research, Inc. Methods and systems for producing ethanol using raw starch and selecting plant material
WO2007046935A2 (en) * 2005-10-14 2007-04-26 Abbott Laboratories Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
WO2007056761A2 (en) 2005-11-09 2007-05-18 C.R. Bard Inc. Grafts and stent grafts having a radiopaque marker
US20080317814A1 (en) * 2005-11-17 2008-12-25 Access Plus Co., Ltd. Tube for Connecting Marteriovenous and Interposition for Medical Operation
US20100204783A1 (en) * 2005-12-06 2010-08-12 Helen Marie Nugent Methods and compositions for enhancing vascular access
BRPI0600275A (pt) * 2006-01-03 2007-10-02 Brz Biotecnologia Ltda prótese coronária liberadora de composição medicamentosa para prevenção e tratamento da reestenose e processo de fabricação
EP2001438A2 (de) 2006-02-09 2008-12-17 Macusight, Inc. Stabile formulierungen sowie verfahren zu ihrer herstellung und verwendung
US8828077B2 (en) * 2006-03-15 2014-09-09 Medinol Ltd. Flat process of preparing drug eluting stents
JP5506378B2 (ja) 2006-03-23 2014-05-28 参天製薬株式会社 血管透過性に関連する疾患または病気のための製剤および方法
US20080133040A1 (en) * 2006-06-16 2008-06-05 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for specifying a blood vessel sleeve
US8478437B2 (en) 2006-06-16 2013-07-02 The Invention Science Fund I, Llc Methods and systems for making a blood vessel sleeve
US8147537B2 (en) * 2006-06-16 2012-04-03 The Invention Science Fund I, Llc Rapid-prototyped custom-fitted blood vessel sleeve
US8550344B2 (en) 2006-06-16 2013-10-08 The Invention Science Fund I, Llc Specialty stents with flow control features or the like
US8163003B2 (en) * 2006-06-16 2012-04-24 The Invention Science Fund I, Llc Active blood vessel sleeve methods and systems
US7818084B2 (en) * 2006-06-16 2010-10-19 The Invention Science Fund, I, LLC Methods and systems for making a blood vessel sleeve
US20080172073A1 (en) * 2006-06-16 2008-07-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Active blood vessel sleeve
US8095382B2 (en) * 2006-06-16 2012-01-10 The Invention Science Fund I, Llc Methods and systems for specifying a blood vessel sleeve
US8551155B2 (en) * 2006-06-16 2013-10-08 The Invention Science Fund I, Llc Stent customization system and method
US20090024152A1 (en) * 2007-07-17 2009-01-22 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Custom-fitted blood vessel sleeve
US7722665B2 (en) 2006-07-07 2010-05-25 Graft Technologies, Inc. System and method for providing a graft in a vascular environment
WO2008008291A2 (en) * 2006-07-13 2008-01-17 Icon Medical Corp. Stent
US20080039362A1 (en) * 2006-08-09 2008-02-14 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation
US20080077070A1 (en) * 2006-08-10 2008-03-27 Kopia Gregory A Arteriovenous shunt
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
US20080085293A1 (en) * 2006-08-22 2008-04-10 Jenchen Yang Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
EP2065056B1 (de) * 2006-08-29 2016-09-28 FUJIFILM Corporation Hydrophile matrix enthaltend einer schwer wasserlöslichen verbindung und herstellungsverfahren dafür
WO2008063780A2 (en) 2006-10-12 2008-05-29 C.R. Bard Inc. Vascular grafts with multiple channels and methods for making
CN103230414A (zh) * 2006-11-07 2013-08-07 夏尔再生医学公司 用于治疗和控制血管生成介导的疾病的材料和方法
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US8741326B2 (en) * 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US8192760B2 (en) 2006-12-04 2012-06-05 Abbott Cardiovascular Systems Inc. Methods and compositions for treating tissue using silk proteins
US8177798B2 (en) 2006-12-05 2012-05-15 Tyco Healthcare Group Lp Adhesive coated stent and insertion instrument
WO2008156705A1 (en) * 2007-06-13 2008-12-24 Pervasis Therapeutics, Inc. Methods and devices for minimally-invasive delivery of cell-containing flowable compositions
US9504469B2 (en) 2007-06-18 2016-11-29 Asfora Ip, Llc Vascular anastomosis device and method
US8361092B1 (en) 2007-06-18 2013-01-29 Wilson T. Asfora Vascular anastomosis device and method
US10004507B2 (en) 2007-06-18 2018-06-26 Asfora Ip, Llc Vascular anastomosis device and method
US8721711B2 (en) * 2007-06-20 2014-05-13 Oregon Health & Science University Graft having microporous membrane for uniform fluid infusion
WO2009073782A2 (en) * 2007-12-04 2009-06-11 Ams Research Corporation Apparatus and methods for treatment of pathologic proliferative conditions of uterine tissue
US8808255B2 (en) * 2007-12-14 2014-08-19 Oregon Health & Science University Drug delivery cuff
EP2268302B1 (de) * 2008-02-13 2014-04-09 Keith Hruska Bmp-7 zur behandlung von neointimaler hyperplasie
WO2009108164A1 (en) * 2008-02-26 2009-09-03 David Chang Method and apparatus for vascular access
AU2009224690B2 (en) 2008-03-13 2014-10-09 Biotest Ag Agent for treating disease
AU2009235622C9 (en) 2008-03-13 2015-07-02 Biotest Ag Agent for treating disease
SG190598A1 (en) 2008-03-13 2013-06-28 Biotest Ag Agent for treating disease
US20090264906A1 (en) * 2008-04-22 2009-10-22 Medtronic Vascular, Inc. Cuff Device
WO2010034590A1 (en) * 2008-09-29 2010-04-01 Biotest Ag Composition for treating disease
KR101034654B1 (ko) * 2009-01-15 2011-05-16 성균관대학교산학협력단 바이오액티브 물질 코팅방법
HUE025623T2 (en) 2009-03-03 2016-04-28 Poet Res Inc A method of fermenting biomass for ethanol production
US8450094B1 (en) 2009-03-03 2013-05-28 Poet Research, Inc. System for management of yeast to facilitate the production of ethanol
US9068206B1 (en) 2009-03-03 2015-06-30 Poet Research, Inc. System for treatment of biomass to facilitate the production of ethanol
WO2010102060A2 (en) * 2009-03-03 2010-09-10 Poet Research, Inc. System for pre-treatment of biomass for the production of ethanol
US20100233266A1 (en) 2009-03-13 2010-09-16 Cleek Robert L Articles and methods of treating vascular conditions
AU2010239605B2 (en) * 2009-04-20 2014-06-26 Rox Medical, Inc. Device and method for establishing an artificial arterio-venous fistula
WO2011006067A1 (en) * 2009-07-09 2011-01-13 Ams Research Corporation Apparatus and methods of treatment of pathologic proliferative conditions uterine tissue
WO2011040652A1 (ko) * 2009-09-29 2011-04-07 주식회사 엠아이텍 이식용 튜브 및 그의 코팅 방법
AU2010324536B2 (en) 2009-11-27 2016-03-03 Stephen Anthony Livesey A method of inducing cellular growth and materials for use therewith
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
US8480620B2 (en) * 2009-12-11 2013-07-09 Abbott Cardiovascular Systems Inc. Coatings with tunable solubility profile for drug-coated balloon
US20110144577A1 (en) * 2009-12-11 2011-06-16 John Stankus Hydrophilic coatings with tunable composition for drug coated balloon
US8951595B2 (en) * 2009-12-11 2015-02-10 Abbott Cardiovascular Systems Inc. Coatings with tunable molecular architecture for drug-coated balloon
CN102933658A (zh) 2009-12-18 2013-02-13 界面生物公司 从自组装涂层局部递送药物
JP2011130989A (ja) * 2009-12-25 2011-07-07 Japan Health Science Foundation 抗血栓性修飾剤、医療用具、及び、多孔質コラーゲン
CA2786282C (en) 2009-12-30 2020-09-08 Caliber Therapeutics, Inc. Balloon catheter systems for delivery of dry drug delivery vesicles to a vessel in the body
US8399044B2 (en) * 2010-01-21 2013-03-19 Snu R And Db Foundation Method for coating medication on medical article
EP2528537A4 (de) * 2010-01-27 2016-09-07 Vascular Therapies Inc Vorrichtung und verfahren zur stenose-verhinderung an einer anastomose-stelle
US8974519B2 (en) 2010-02-19 2015-03-10 Cardiovascular Systems, Inc. Therapeutic agent delivery system, device and method for localized application of therapeutic substances to a biological conduit
US8398916B2 (en) 2010-03-04 2013-03-19 Icon Medical Corp. Method for forming a tubular medical device
ES2656939T3 (es) * 2010-03-09 2018-03-01 Solinas Medical Inc. Dispositivos de cierre automático
IT1400232B1 (it) * 2010-05-07 2013-05-24 Advance Holdings Ltd Composizione farmaceutica topica comprendente eparina
US10350431B2 (en) * 2011-04-28 2019-07-16 Gt Medical Technologies, Inc. Customizable radioactive carriers and loading system
CN109172809A (zh) 2011-04-28 2019-01-11 阿布拉科斯生物科学有限公司 纳米颗粒组合物的血管内递送及其应用
WO2012159169A1 (en) * 2011-05-26 2012-11-29 Kathy Traianedes A method of ex vivo cellular growth
US8577693B2 (en) 2011-07-13 2013-11-05 The Invention Science Fund I, Llc Specialty stents with flow control features or the like
US9433722B2 (en) * 2011-08-09 2016-09-06 Abbott Cardiovascular Systems Inc. Vascular shield and delivery system
MX368037B (es) 2012-01-09 2019-09-17 Innocoll Pharm Ltd Colágeno modificado.
US20130303983A1 (en) * 2012-05-09 2013-11-14 Cook Medical Technologies Llc Coated medical devices including a water-insoluble therapeutic agent
CA2889981A1 (en) 2012-10-29 2014-05-08 Ariste Medical, Inc. Polymer coating compositions and coated products
WO2014127278A2 (en) * 2013-02-18 2014-08-21 Elutin, Inc. Site specific drug delivery wraps, systems and methods of use thereof
US9492683B2 (en) 2013-03-15 2016-11-15 Gammatile Llc Dosimetrically customizable brachytherapy carriers and methods thereof in the treatment of tumors
US20150119908A1 (en) * 2013-10-25 2015-04-30 Abbott Cardiovascular Systems Inc. Extravascular devices supporting an arteriovenous fistula
US20150119976A1 (en) * 2013-10-29 2015-04-30 Abbott Cardiovascular Systems Inc. Extravascular device for limiting blood flow adjacent an arteriovenous fistula
US9687239B2 (en) 2014-04-15 2017-06-27 Abbott Cardiovascular Systems Inc. Intravascular devices supporting an arteriovenous fistula
WO2015164524A1 (en) 2014-04-22 2015-10-29 Ariste Medical, Inc. Methods and processes for application of drug delivery polymeric coatings
CN106535826A (zh) 2014-06-24 2017-03-22 怡康医疗股份有限公司 用于医疗装置的改进的金属合金
US20160193390A1 (en) * 2015-01-05 2016-07-07 Wisconsin Alumni Research Foundation Perivascular Delivery System And Method
WO2016123051A1 (en) * 2015-01-26 2016-08-04 Mercator Medsystems, Inc. Methods and systems for inhibiting vascular inflammation
US9821174B1 (en) 2015-02-06 2017-11-21 Gammatile Llc Radioactive implant planning system and placement guide system
US9907680B2 (en) * 2015-04-10 2018-03-06 Cook Medical Technologies Llc Sliding fenestration
US11766506B2 (en) 2016-03-04 2023-09-26 Mirus Llc Stent device for spinal fusion
US10888710B1 (en) 2016-11-29 2021-01-12 Gt Medical Technologies, Inc. Transparent loading apparatus
EP3796948A4 (de) 2018-05-22 2022-03-02 Interface Biologics Inc. Zusammensetzungen und verfahren zur verabreichung von arzneimitteln an eine gefässwand
DE102018127200B3 (de) * 2018-10-31 2019-07-25 Andreas Haas Implantat zum subkutanen implantieren
CN111012409A (zh) * 2019-12-03 2020-04-17 王超 颞浅动脉额支与脑动脉皮层血运重建辅助三通及使用方法
CN114259607B (zh) * 2021-12-28 2023-01-24 宇航 一种支架制备方法
WO2024068153A1 (en) 2022-09-30 2024-04-04 Biotronik Ag Macrocyclic triene immunosuppressive compounds for perivascular medical treatment of vascular access fistulas, grafts and other vascular conditions
WO2024068159A1 (en) 2022-09-30 2024-04-04 Biotronik Ag Synthesis and characterization of cyclic hydrocarbon esters of everolimus

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU471719A3 (ru) 1969-07-19 1975-05-25 Шеринг Аг (Фирма) Способ получени нитрофуриламиноалкоксипиримидина
US3797485A (en) 1971-03-26 1974-03-19 Alza Corp Novel drug delivery device for administering drug into blood circulation in blood vessel
US4391797A (en) 1977-01-05 1983-07-05 The Children's Hospital Medical Center Systems for the controlled release of macromolecules
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
US4409332A (en) 1982-01-12 1983-10-11 Jefferies Steven R Collagen-enzyme conjugates that exhibit no inflammatory response and method for making the same
US4677120A (en) 1985-07-31 1987-06-30 Molecular Design International Topical prodrugs for treatment of acne and skin diseases
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US4889842A (en) 1987-03-03 1989-12-26 Morris Randall E Concanavalin A dimers as therapeutic agents
US5124356A (en) 1987-06-29 1992-06-23 Molecular Design International, Inc. Dermal uses of trans-retinoids for the treatment of photoaging
US4885311A (en) 1987-06-29 1989-12-05 Molecular Design International Topical transretinoids for treatment of acne and skin diseases
US4994491A (en) 1988-12-14 1991-02-19 Molecular Design International Dermal uses of trans-retinoids for the treatment of cancer
US4840940A (en) 1987-10-21 1989-06-20 Sottiurai Vikrom S Method for reducing the occurrence of distal anastomotic intimal hyperplasia using fractionated heparin
US5157049A (en) 1988-03-07 1992-10-20 The United States Of America As Represented By The Department Of Health & Human Services Method of treating cancers sensitive to treatment with water soluble derivatives of taxol
US5100668A (en) 1988-06-14 1992-03-31 Massachusetts Institute Of Technology Controlled release systems containing heparin and growth factors
US5074869A (en) * 1988-09-26 1991-12-24 Daicoff George R Vascular occlusion device
US5049584A (en) 1988-12-14 1991-09-17 Molecular Design International Dermal uses of cis-retinoids for the treatment of cancer
US5223269A (en) 1989-08-31 1993-06-29 Andrejs Liepins Methods and composition for the treatment of hypertension
US6326017B1 (en) 1989-10-02 2001-12-04 University Of Washington Methods for the localized delivery of agents to blood vessels
WO1991007154A1 (en) 1989-11-13 1991-05-30 President And Fellows Of Harvard College EXTRALUMINAL REGULATION OF THE GROWTH AND REPAIR OF TUBULAR STRUCTURES ιIN VIVO
US5527532A (en) * 1989-11-13 1996-06-18 President And Fellows Of Harvard College Extraluminal regulation of the growth and repair of tubular structures in vivo
US5540928A (en) 1991-02-27 1996-07-30 President And Fellows Of Harvard College Extraluminal regulation of the growth and repair of tubular structures in vivo
US5138051A (en) 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
EP0558697A1 (de) 1991-06-28 1993-09-08 Massachusetts Institute Of Technology Lokale oligonukleotiden Behandlung
US5169851A (en) 1991-08-07 1992-12-08 American Home Products Corporation Rapamycin analog as immunosuppressants and antifungals
US5202332A (en) 1991-08-07 1993-04-13 American Home Products Corporation Rapamycin analog as immunosuppressant
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
AU669338B2 (en) 1991-10-25 1996-06-06 Cook Incorporated Expandable transluminal graft prosthesis for repair of aneurysm and method for implanting
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
IT1254915B (it) * 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
WO1993023013A1 (en) * 1992-05-20 1993-11-25 New England Deaconess Hospital Extravascular system for infusion of soluble substances
US5283257A (en) 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5480988A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2092271C (en) 1993-03-09 2009-10-13 Eddie Reed Use of g-csf for treating taxol side-effects
US5703247A (en) 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
US5571800A (en) 1993-05-17 1996-11-05 Azura, Inc. Method for inhibiting allograft rejection by the administration of 6-azauridine or its triacetate derivative
CA2161328A1 (en) 1993-06-11 1994-12-22 Robert C. Kelly Delta 6,7-taxols antineoplastic use and pharmaceutical compositions containing them
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
EP1118325B2 (de) 1993-07-29 2010-01-06 The United States of America, represented by the Secretary, Department of Health and Human Services Verwendung von Paclitaxel und seinen Derivaten zur Herstellung eines Medikaments für die Behandlung von Restenose
US6323184B1 (en) 1993-10-15 2001-11-27 Thomas Jefferson University Arteriovenous and venous graft treatments: methods and compositions
US5519042A (en) 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
IL127597A (en) 1994-01-28 2003-07-31 Upjohn Co Iso-taxol analogs
DE69524501T2 (de) 1994-08-12 2002-05-29 Meadox Medicals Inc Mit einen Heparin enhaltendes Kollagendichtmittel imprägniertes Gefässtransplantat
US5660873A (en) 1994-09-09 1997-08-26 Bioseal, Limited Liability Corporaton Coating intraluminal stents
US5616680A (en) * 1994-10-04 1997-04-01 Hoechst Celanese Corporation Process for producing liquid crystal polymer
US5837728A (en) 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US5766584A (en) 1995-06-02 1998-06-16 Massachusetts Institute Of Technology Inhibition of vascular smooth muscle cell proliferation with implanted matrix containing vascular endothelial cells
AU716005B2 (en) 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
US5780653A (en) 1995-06-07 1998-07-14 Vivorx Pharmaceuticals, Inc. Nitrophenyl, 10-deacetylated substituted taxol derivatives as dual functional cytotoxic/radiosensitizers
AU7360396A (en) 1995-09-11 1997-04-01 Enzymed, Inc. Biocatalytic methods for synthesizing and identifying biologically active compounds
US5795286A (en) * 1996-08-15 1998-08-18 Cathco, Inc. Radioisotope impregnated sheet of biocompatible material for preventing scar tissue formation
SK22499A3 (en) 1996-08-23 1999-10-08 Cook Biotech Inc Graft prosthesis, materials and methods
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6090996A (en) 1997-08-04 2000-07-18 Collagen Matrix, Inc. Implant matrix
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6117166A (en) 1997-10-27 2000-09-12 Winston; Thomas R. Apparatus and methods for grafting blood vessel tissue
US6224794B1 (en) 1998-05-06 2001-05-01 Angiotech Pharmaceuticals, Inc. Methods for microsphere production
US6091980A (en) 1998-05-12 2000-07-18 Massachusetts Institute Of Technology Stent slip sensing system and method
US6179858B1 (en) 1998-05-12 2001-01-30 Massachusetts Institute Of Technology Stent expansion and apposition sensing
NZ510121A (en) * 1998-10-26 2003-02-28 Licentia Ltd Use of VEGF-C or VEGF-D gene or protein to prevent restenosis of blood vessels
DE19849589C1 (de) 1998-10-27 2000-06-15 Glatt Process Technology Gmbh Fibrin-Gewebekleber-Formulierung und Verfahren zu dessen Herstellung
US6333347B1 (en) 1999-01-29 2001-12-25 Angiotech Pharmaceuticals & Advanced Research Tech Intrapericardial delivery of anti-microtubule agents
US6391333B1 (en) 1999-04-14 2002-05-21 Collagen Matrix, Inc. Oriented biopolymeric membrane
US6328762B1 (en) 1999-04-27 2001-12-11 Sulzer Biologics, Inc. Prosthetic grafts
WO2001054748A1 (en) 2000-01-25 2001-08-02 Edwards Lifesciences Corporation Delivery systems for treatment of restenosis and anastomotic intimal hyperplasia
US6746773B2 (en) 2000-09-29 2004-06-08 Ethicon, Inc. Coatings for medical devices
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
PE20091074A1 (es) 2007-12-13 2009-07-26 Bayer Healthcare Ag Triazolotriazinas y triazolopirazinas y su uso

Also Published As

Publication number Publication date
JP2009119257A (ja) 2009-06-04
US8858982B2 (en) 2014-10-14
CA2434972C (en) 2010-06-08
RU2003125357A (ru) 2005-03-10
BR0206464A (pt) 2005-01-18
EP2314293B1 (de) 2017-01-04
EP1351681B1 (de) 2010-09-15
RU2345719C2 (ru) 2009-02-10
NZ527046A (en) 2005-06-24
US20030113359A1 (en) 2003-06-19
ATE481097T1 (de) 2010-10-15
JP4584537B2 (ja) 2010-11-24
US20150209334A1 (en) 2015-07-30
JP2004523537A (ja) 2004-08-05
AU2002249958B2 (en) 2007-11-08
DK2314293T3 (en) 2017-04-18
ES2621652T3 (es) 2017-07-04
US20190201383A1 (en) 2019-07-04
EP1351681A2 (de) 2003-10-15
WO2002062335A3 (en) 2002-12-27
US7807191B2 (en) 2010-10-05
WO2002062335A2 (en) 2002-08-15
CN1492759A (zh) 2004-04-28
JP5748389B2 (ja) 2015-07-15
CA2434972A1 (en) 2002-08-15
US10272073B2 (en) 2019-04-30
AP2003002828A0 (en) 2003-09-30
PT2314293T (pt) 2017-04-11
US20080091263A1 (en) 2008-04-17
CY1119109T1 (el) 2018-02-14
US20040197409A1 (en) 2004-10-07
US6726923B2 (en) 2004-04-27
EP2314293A1 (de) 2011-04-27
MXPA03006315A (es) 2004-12-03

Similar Documents

Publication Publication Date Title
DE60237671D1 (de) Implantierbare vorrichtung enthaltend resorbierbares matrixmaterial und antiproliferative wirkstoffe zur vorbeugung oder behandlung von versagen vaskulärer hämodialysezugänge und anderer vaskulärer transplantate
ATE349428T1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE69832838D1 (de) Vorrichtung zur Aufbewahrung und/oder Behandlung von Chemikalien
DE69332732D1 (de) Pharmazeutische Zusammensetzung und Methode zur Behandlung von Hyperlipidämie und Arterioskerose
DE60027894D1 (de) Milchsäurebakterienkombination und deren verwendung zur behandlung und prävention von infektionen und entzündungen
ATE229502T1 (de) Arylsulfonamide und analoga und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
DE60109589D1 (de) Pharmazeutische zusammensetzung zur behandlung von akutem schmerz, chronischem schmerz und/oder neuropathischem schmerz und migräne
ATE255888T1 (de) Tetrahydronaphtalene verbindungen und deren verwendung zur behandlung von neurodegenerativen krankheiten
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE60010456D1 (de) Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie
DE69929996D1 (de) Pharmazeutisches mittel zur behandlung von diabetes
DE69917625D1 (de) Implantate zur verabreichung von wirkstoffen und verfahren zum herstellen von implantaten
DE60140377D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
DE60324777D1 (de) Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten
ATA11989A (de) Mittel zur vorbeugung gegen und behandlung von parodontopathien
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE69625883T2 (de) Zusammensetzung zur Reinigung und/oder Desinfektion von medizinischen Geräten
DE69825319D1 (de) Präparat zur vorbeugung und behandlung von entzündungen
DE60224004D1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
DE69939075D1 (de) Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten
DE69832722D1 (de) L-threonat-eisen, pharmazeutische zusammensetzung und verwendung zur verbesserung und behandlung von anämie bei menschen
DE1083796T1 (de) Vorbeugende und heilende verfahren und zusammensetzungen zur biologischen kontrolle des verderbs von erntegut
ATE193450T1 (de) Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von knochenbrüchen
DE602004017613D1 (de) Pharmazeutische zusammensetzungen mit ascorbinsäure zur behandlung von pilz-superinfektionen und pilz-rezidiven
DE60219189D1 (de) Iontophoretische okularvorrichtung zur abgabe von medikamenten auf methotrexat-basis und deren verwendung zur behandlung von neoplastischen, angiogenen, fibroplastischen und/oder immunsuppressiven augenunregelmässigkeiten